Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I
Department of Obstetrics and Gynecology, University Hospital, Malmö, Sweden.
Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):85-92. doi: 10.1016/s0002-9378(96)70378-2.
We studied the efficacy, safety, and acceptability of an estradiol-releasing (6.5 to 9.5 micrograms per 24 hours) silicone vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging during a treatment period of 1 year.
The study was open with blind analysis of vaginal cytologic testing. In addition to gynecologic examination, subjective symptoms were assessed and vaginal pH and urinary samples (for bacteriuria) were obtained before insertion of Estring. This procedure was repeated every 3 months up to 1 year's treatment, together with requests concerning acceptability and adverse experiences. At inclusion and end of Estring treatment, vaginal smears for evaluation of cytologic results were obtained.
Estring induced a high maturation value in the vaginal mucosa and restored vaginal pH to levels normality seen in fertile women (< 5.5). For most variables a 90% responder rate (proportion of cured and improved patients) was found after 3 months and up to 1 year regarding subjective symptoms and objective signs of vaginal mucosal atrophy. Twenty-eight (20%) of 136 women, withdrew from the study, 8 (6%) of them because of adverse events. Three women reported vaginal bleeding, none associated with malignancy or endometrial proliferation. Ten (7%) reported vaginal irritation, and in two cases vaginal ulcers were found. About 90% did not remove the ring during any of the 3-month treatment periods, and 78% used the four consecutive rings continuously up to 1 year. The ring was given a strong preference (p < 0.001) by patients with previous experience of other administration forms.
Estring represents a safe, highly effective, and very well-accepted administration form for long-term treatment of urogenital disorders caused by estrogen deficiency in postmenopausal women.
我们研究了一种释放雌二醇(每24小时6.5至9.5微克)的硅胶阴道环(爱斯妥)在有泌尿生殖系统老化症状和体征的绝经后妇女中进行1年治疗期间的疗效、安全性和可接受性。
该研究为开放性研究,对阴道细胞学检测进行盲法分析。除妇科检查外,在插入爱斯妥前评估主观症状,并获取阴道pH值和尿液样本(用于检测菌尿)。此操作每3个月重复一次,直至治疗1年,同时询问有关可接受性和不良经历的情况。在纳入研究时和爱斯妥治疗结束时,获取阴道涂片以评估细胞学结果。
爱斯妥使阴道黏膜成熟值升高,并将阴道pH值恢复到育龄妇女的正常水平(<5.5)。对于大多数变量,在3个月后以及长达1年的时间里,关于阴道黏膜萎缩的主观症状和客观体征,发现有90%的有效率(治愈和改善患者的比例)。136名妇女中有28名(20%)退出研究,其中8名(6%)是因为不良事件。3名妇女报告有阴道出血,均与恶性肿瘤或子宫内膜增生无关。10名(7%)报告有阴道刺激,2例发现有阴道溃疡。约90%的妇女在任何一个3个月治疗期内都未取出阴道环,78%的妇女连续使用4个阴道环长达1年。有其他给药方式既往经验的患者对该阴道环有强烈偏好(p<0.001)。
爱斯妥是一种安全、高效且非常易于接受的给药方式,用于长期治疗绝经后妇女因雌激素缺乏引起的泌尿生殖系统疾病。